ClinicalTrials.gg
CompletedNCT00654498Updated Jun 9, 2014Results posted

Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)

A Phase 3 interventional study of Pramipexole and Placebo in Restless Legs Syndrome, sponsored by Boehringer Ingelheim. Completed at 16 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-06-09.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
306
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing pramipexole in Restless Legs Syndrome — none open to participants now, 1 under way, none of them phase 3. Pramipexole · Restless Legs Syndrome.

Enrollment
7th of 17
306 · median 154
Started
2008
the only one that year
Phase 3
6 of 17
none open now
Registered
13th of 17
by date
Lead sponsor
12 of 17
Boehringer Ingelheim

Among the 17 studies testing pramipexole in Restless Legs Syndrome, this one is the 7th largest by enrollment, is the only one that started in 2008, is one of 6 in phase 3, and was the 13th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

None of the 17 studies testing pramipexole in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing pramipexole in Restless Legs Syndrome as a file.
02

Study summary

To determine efficacy and safety of Pramipexole 0.125mg to 0.75mg daily for 6 weeks compared to placebo in the treatment of idiopathic Restless Legs Syndrome (RLS)

03

Conditions studied

  • Restless Legs Syndrome
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written consistent with International Conference on Harmonisation (ICH) / Good Clinical Practice (GCP) and local legislation given prior to any study procedures.
  2. Ability and willingness to comply with study treatment regimen and to attend study assessments.
  3. Male or female out-patients aged 18-80 years.
  4. Diagnosis of idiopathic Restless Legs Syndrome (IRLS) according to the clinical Restless Legs Syndrome (RLS) criteria of the International Restless Legs Syndrome Study Group (IRLSSG)

    All four criteria must be present to fulfil the diagnosis of RLS:

    • An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs. (Sometimes the urge to move is present without the uncomfortable sensations and sometimes the arms or other body parts are involved in addition to the legs).
    • The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting.
    • The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.
    • The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night. (When symptoms are very severe, the worsening at night may not be noticeable but must have been previously present).
  5. Restless Legs Syndrome (RLS)rating scale for severity total score >15.
  6. Restless Legs Syndrome (RLS) symptoms present at least 2 to 3 days per week during the last 3 months.

Exclusion criteria

Exclusion Criteria:

  1. Women of (i.e. premenopausal women, or women less than 2 years after last menses) who do not use during the clinical trial an adequate method of such as: hormonal therapy (combined oral contraceptives, injectables, or subcutaneous implants), hormonal intrauterine devices, sexual abstinence, surgical sterilization of patient and/or partner, hysterectomy, bilateral ovariectomy or partners vasectomy
  2. Any woman of child-bearing potential not having a negative pregnancy test at screening
  3. Patients who are breastfeeding
  4. Concomitant or previous pharmacologically therapy of RLS as follows:

    • Any intake of levodopa within 5 days prior to baseline visit (V2)
    • Any intake of dopamine agonists within 14 days prior to baseline visit (V2)
  5. Current (less than 14 days before treatment with trial medication or concomitant) treatment with medication or dietary supplements, which could significantly influence RLS symptoms, e.g. dopaminergic (other than levodopa or dopamine agonists) or anti-dopaminergic drugs, non-selective Monoamine Oxidase (MAO) inhibitors, sympathomimetics, neuroleptics, anti-depressants, hypnotics, any benzodiazepines, antiepileptics, opioids, clonidine, magnesium, ferrous salts, Folic acid, vitamin B12, antihistaminics, lithium, metoclopramide or Withdrawal symptoms caused by stopping any of the drugs above
  6. Confirmed diagnose of diabetic nephropathy or renal disease
  7. Creatinine higher than (ULN) at screening
  8. Clinical significant hepatic disease or (ALT) >2 times the upper limit of normal range at screening
  9. Clinical or laboratory signs of microcytic anaemia, or ferritin in serum below the lower bound of the reference range
  10. Any of the following lab results at screening:

    • Basal Thyroid Stimulating Hormone (TSH), T3 or T4 clinically significantly (at the investigators discretion) out of normal range at screening (if not caused by substitution therapy according the investigators opinion)
    • Patients with any clinically significant abnormalities in laboratory parameters at screening at the investigators discretion
  11. Other clinically significant metabolic-endocrine, haematological, gastro-intestinal disease or pulmonary disease (such as severe ). Poorly controlled cardiovascular disease (including hypotension and severe coronary artery disease)
  12. History or clinical signs of peripheral neuropathy (PNP) of any origin in physical, neuro-logical examination, myelopathy or multiple sclerosis or any other neurological disease, with potential to secondarily cause RLS symptoms
  13. Presence of any other sleep disorder, such as, Rapid Eye Movement (REM) sleep behaviour disorder, narcolepsy or sleep apnoea syndrome
  14. History of Schizophrenia or any psychotic disorder, history of mental disorders due to a general medical condition or any present axis I psychiatric disorder according to , fourth edition (DSM IV) requiring any medical therapy
  15. History of alcohol abuse or drug addiction within the last 2 years before screening
  16. Participation in a drug study within two months prior to the start of this study
  17. History of or clinical signs for any form of epilepsy or seizures apart from fever related seizures in early childhood
  18. History of or clinical signs of malign neoplasm
  19. Patients on a shift-work-schedule, or who are otherwise unable to follow a regular sleep-wake cycle enabling use of study medication at times indicated
  20. Any other conditions that in the opinion of the investigator would interfere with the evaluation of the results or constitute a health hazard for the subject
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
306 participants (actual)

Study arms

  • Other
    Pramipexole

    4 weeks of individual dose titration starting with Pramipexole 0.125 mg, next dose steps 0.25 mg, 0.5 mg and 0.75 mg, fixed dose for 2 weeks, once daily

    Drug: Pramipexole

  • Other
    Placebo

    4 weeks of individual dose titration as for the investigational product, once daily

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. The Change From Baseline to Week 6 in the Total Score of Restless Legs Syndrome Rating Scale for Severity of the International Restless Legs Syndrome Study Group (IRLS).

    The IRLS was a 10-item self patient's rating scale for assessing severity of restless legs syndrome symptoms with each item ranging from 0 (no symptoms) to 4 (very severe symptoms). The total IRLS score ranges from 0 (no symptoms) to 40 (worst possible symptoms).

    Time frame: Baseline and 6 weeks of treatment

  2. The Proportion of Patients With Clinical Global Impressions -Improvement Scale (CGI-I) Assessment of "Much Improved" and "Very Much Improved"

    CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved)and 2 (much improved.

    Time frame: 6 weeks of treatment

Secondary outcomes

  1. The Proportion of IRLS Responders

    responders is defined as the total score in IRLS changed ≥ 50%from baseline calculated in the full analysis set population.

    Time frame: 6 weeks of treatment

  2. The Proportion of Patient Global Impression(PGI) Responders

    PGI was a one-question scale with 7 degrees to assess patient's overall condition, ranging from very much better to very much worse. The responder are defined as patients with their assessment of "much better" or "very much better".

    Time frame: 6 weeks of treatment

  3. The Proportion of Patients With Epworth Sleepiness Scale (ESS) Categorised >10

    The ESS is a self-administered instrument to assess the patients likelihood of falling asleep in various activities of daily living; the maximum score is 24 indicating a very high level of daytime sleepiness and a high likelihood of falling asleep.

    Time frame: week 6 of treatment

  4. the Mean Change From Baseline to Week 6 in Satisfaction of Sleep at Night of RLS-6 Rating Scales

    RLS-6 rating scales comprises 6 questions Satisfaction of sleep is one of the 6 questions. The patient should give a rate between 0 (none/Not at all) to 10 (very severe) for the satisfaction of sleep.

    Time frame: Baseline and 6 weeks of treatment

  5. The Mean Change From Baseline in the Severity of RLS at Time of Falling Sleep of RLS-6 Rating Scales.

    RLS-6 rating scales comprises 6 questions. The severity of RLS at time of falling sleep is one of the 6 questions. The patient should give a rate between 0 (none/Not at all) to 10 (very severe) for the severity of RLS at time of falling sleep

    Time frame: Baseline and 6 weeks of treatment

  6. The Mean Change From Baseline in the Severity of RLS During the Night of RLS-6 Rating Scales.

    RLS-6 rating scales comprises 6 questions. The severity of RLS during the night is one of the 6 questions. The patient should give a rate between 0 ("none/Not at all") to 10 ("very severe") for the severity of RLS during the night.

    Time frame: Baseline and 6 weeks of treatment

  7. The Mean Change From Baseline in the Severity of RLS During the Rest at Day of RLS-6 Rating Scales.

    RLS-6 rating scales comprises 6 questions. The severity of RLS during the test at day is one of the 6 questions. The patient should give a rate between 0 ("none/Not at all") to 10 ("very severe") for the severity of RLS during the rest at day.

    Time frame: Baseline and 6 weeks of treatment

  8. The Mean Change From Baseline in the Severity of RLS During the Activities at Day of RLS-6 Rating Scale

    RLS-6 rating scales comprises 6 questions. The severity of RLS during the activities at day is one of the 6 questions. The patient should give a rate between 0 ("none/Not at all") to 10 ("very severe") for the severity of RLS during the activity at day.

    Time frame: Baseline and 6 weeks of treatment

  9. The Mean Change From Baseline in the Intensity of Tiredness and Sleepiness at Day of RLS-6 Rating Scale

    RLS-6 rating scales comprises 6 questions. The intensity of tiredness and sleepiness at day is one of the 6 questions. The patient should give a rate between 0 ("none/Not at all") to 10 ("very severe") for the intensity of tiredness and sleepiness at day.

    Time frame: Baseline and 6 weeks of treatment

  10. The Change From Baseline in Visual Analogue Scales (VAS)

    VAS is for assessment of RLS-associated pain. The patient was asked "How severe was your RLS associated pain in legs or arms during the past week?". No pain:0; very worst pain:10

    Time frame: Baseline and 6 weeks of treatment

07

Results

Posted Mar 3, 2010

Participant flow

Participant flow — Overall Study
MilestonePramipexolePlacebo
Started203103
Completed18991
Not completed1412
Withdrew: Not treated10
Withdrew: Adverse event61
Withdrew: Protocol violation11
Withdrew: Lost to follow-up15
Withdrew: Withdrawal by subject10
Withdrew: Other reason not defined above45

Outcome measures

PrimaryThe Change From Baseline to Week 6 in the Total Score of Restless Legs Syndrome Rating Scale for Severity of the International Restless Legs Syndrome Study Group (IRLS).

The IRLS was a 10-item self patient's rating scale for assessing severity of restless legs syndrome symptoms with each item ranging from 0 (no symptoms) to 4 (very severe symptoms). The total IRLS score ranges from 0 (no symptoms) to 40 (worst possible symptoms).

Time frame:
Baseline and 6 weeks of treatment
Reported as:
Least squares mean · Score on a scale
The Change From Baseline to Week 6 in the Total Score of Restless Legs Syndrome Rating Scale for Severity of the International Restless Legs Syndrome Study Group (IRLS).
Score on a scalePramipexolePlacebo
The Change From Baseline to Week 6 in the Total Score of Restless Legs Syndrome Rating Scale for Severity of the International Restless Legs Syndrome Study Group (IRLS).-15.87 ± 0.66-11.35 ± 0.92
Statistical analysis
  • Pramipexole vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -4.52 · 95% CI -6.58 to -2.46ANCOVA with treatment and center as fixed factors and baseline as a covariate
PrimaryThe Proportion of Patients With Clinical Global Impressions -Improvement Scale (CGI-I) Assessment of "Much Improved" and "Very Much Improved"

CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved)and 2 (much improved.

Time frame:
6 weeks of treatment
Reported as:
Number · Proportion of Patients
The Proportion of Patients With Clinical Global Impressions -Improvement Scale (CGI-I) Assessment of "Much Improved" and "Very Much Improved"
Proportion of PatientsPramipexolePlacebo
The Proportion of Patients With Clinical Global Impressions -Improvement Scale (CGI-I) Assessment of "Much Improved" and "Very Much Improved"0.8190.543
Statistical analysis
  • Pramipexole vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001test stratified by centre
SecondaryThe Proportion of IRLS Responders

responders is defined as the total score in IRLS changed ≥ 50%from baseline calculated in the full analysis set population.

Time frame:
6 weeks of treatment
Reported as:
Number · Proportion of Patients
The Proportion of IRLS Responders
Proportion of PatientsPramipexolePlacebo
The Proportion of IRLS Responders0.7380.489
Statistical analysis
  • Pramipexole vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001test stratified by centre
SecondaryThe Proportion of Patient Global Impression(PGI) Responders

PGI was a one-question scale with 7 degrees to assess patient's overall condition, ranging from very much better to very much worse. The responder are defined as patients with their assessment of "much better" or "very much better".

Time frame:
6 weeks of treatment
Reported as:
Number · Proportion of participants
The Proportion of Patient Global Impression(PGI) Responders
Proportion of participantsPramipexolePlacebo
The Proportion of Patient Global Impression(PGI) Responders0.6860.435
Statistical analysis
  • Pramipexole vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001test stratified by centre
SecondaryThe Proportion of Patients With Epworth Sleepiness Scale (ESS) Categorised >10

The ESS is a self-administered instrument to assess the patients likelihood of falling asleep in various activities of daily living; the maximum score is 24 indicating a very high level of daytime sleepiness and a high likelihood of falling asleep.

Time frame:
week 6 of treatment
Reported as:
Number · Proportion of Patients
The Proportion of Patients With Epworth Sleepiness Scale (ESS) Categorised >10
Proportion of PatientsPramipexolePlacebo
The Proportion of Patients With Epworth Sleepiness Scale (ESS) Categorised >100.1080.054
Statistical analysis
  • Pramipexole vs Placebo · Chi-squared · p = 0.1386
Secondarythe Mean Change From Baseline to Week 6 in Satisfaction of Sleep at Night of RLS-6 Rating Scales

RLS-6 rating scales comprises 6 questions Satisfaction of sleep is one of the 6 questions. The patient should give a rate between 0 (none/Not at all) to 10 (very severe) for the satisfaction of sleep.

Time frame:
Baseline and 6 weeks of treatment
Reported as:
Mean · Score on a scale
the Mean Change From Baseline to Week 6 in Satisfaction of Sleep at Night of RLS-6 Rating Scales
Score on a scalePramipexolePlacebo
the Mean Change From Baseline to Week 6 in Satisfaction of Sleep at Night of RLS-6 Rating Scales-4.52 ± 0.21-3.04 ± 0.3
Statistical analysis
  • Pramipexole vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -1.48 · 95% CI -2.14 to -0.83ANCOVA with treatment and center as fixed factors and baseline as a covariate
SecondaryThe Mean Change From Baseline in the Severity of RLS at Time of Falling Sleep of RLS-6 Rating Scales.

RLS-6 rating scales comprises 6 questions. The severity of RLS at time of falling sleep is one of the 6 questions. The patient should give a rate between 0 (none/Not at all) to 10 (very severe) for the severity of RLS at time of falling sleep

Time frame:
Baseline and 6 weeks of treatment
Reported as:
Mean · Score on a scale
The Mean Change From Baseline in the Severity of RLS at Time of Falling Sleep of RLS-6 Rating Scales.
Score on a scalePramipexolePlacebo
The Mean Change From Baseline in the Severity of RLS at Time of Falling Sleep of RLS-6 Rating Scales.-4.9 ± 0.21-3.53 ± 0.28
Statistical analysis
  • Pramipexole vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -1.36 · 95% CI -1.99 to -0.73ANCOVA with treatment and center as fixed factors and baseline as a covariate
SecondaryThe Mean Change From Baseline in the Severity of RLS During the Night of RLS-6 Rating Scales.

RLS-6 rating scales comprises 6 questions. The severity of RLS during the night is one of the 6 questions. The patient should give a rate between 0 ("none/Not at all") to 10 ("very severe") for the severity of RLS during the night.

Time frame:
Baseline and 6 weeks of treatment
Reported as:
Mean · Score on a scale
The Mean Change From Baseline in the Severity of RLS During the Night of RLS-6 Rating Scales.
Score on a scalePramipexolePlacebo
The Mean Change From Baseline in the Severity of RLS During the Night of RLS-6 Rating Scales.-4.68 ± 0.21-3.32 ± 0.29
Statistical analysis
  • Pramipexole vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -1.36 · 95% CI -2.00 to -0.72ANCOVA with treatment and center as fixed factors and baseline as a covariate
SecondaryThe Mean Change From Baseline in the Severity of RLS During the Rest at Day of RLS-6 Rating Scales.

RLS-6 rating scales comprises 6 questions. The severity of RLS during the test at day is one of the 6 questions. The patient should give a rate between 0 ("none/Not at all") to 10 ("very severe") for the severity of RLS during the rest at day.

Time frame:
Baseline and 6 weeks of treatment
Reported as:
Mean · Score on a scale
The Mean Change From Baseline in the Severity of RLS During the Rest at Day of RLS-6 Rating Scales.
Score on a scalePramipexolePlacebo
The Mean Change From Baseline in the Severity of RLS During the Rest at Day of RLS-6 Rating Scales.-2.9 ± 0.17-2.36 ± 0.23
Statistical analysis
  • Pramipexole vs Placebo · ANCOVA · p = 0.0402 · Mean difference (final values): -0.54 · 95% CI -1.06 to -0.02ANCOVA with treatment and center as fixed factors and baseline as a covariate
SecondaryThe Mean Change From Baseline in the Severity of RLS During the Activities at Day of RLS-6 Rating Scale

RLS-6 rating scales comprises 6 questions. The severity of RLS during the activities at day is one of the 6 questions. The patient should give a rate between 0 ("none/Not at all") to 10 ("very severe") for the severity of RLS during the activity at day.

Time frame:
Baseline and 6 weeks of treatment
Reported as:
Mean · Score on a scale
The Mean Change From Baseline in the Severity of RLS During the Activities at Day of RLS-6 Rating Scale
Score on a scalePramipexolePlacebo
The Mean Change From Baseline in the Severity of RLS During the Activities at Day of RLS-6 Rating Scale-0.93 ± 0.12-0.61 ± 0.16
Statistical analysis
  • Pramipexole vs Placebo · ANCOVA · p = 0.0771 · Mean difference (final values): -0.33 · 95% CI -0.69 to 0.04ANCOVA with treatment and center as fixed factors and baseline as a covariate
SecondaryThe Mean Change From Baseline in the Intensity of Tiredness and Sleepiness at Day of RLS-6 Rating Scale

RLS-6 rating scales comprises 6 questions. The intensity of tiredness and sleepiness at day is one of the 6 questions. The patient should give a rate between 0 ("none/Not at all") to 10 ("very severe") for the intensity of tiredness and sleepiness at day.

Time frame:
Baseline and 6 weeks of treatment
Reported as:
Mean · Score on a scale
The Mean Change From Baseline in the Intensity of Tiredness and Sleepiness at Day of RLS-6 Rating Scale
Score on a scalePramipexolePlacebo
The Mean Change From Baseline in the Intensity of Tiredness and Sleepiness at Day of RLS-6 Rating Scale-2.96 ± 0.16-2.25 ± 0.22
Statistical analysis
  • Pramipexole vs Placebo · ANCOVA · p = 0.0048 · Mean difference (final values): -0.71 · 95% CI -1.20 to -0.22ANCOVA with treatment and center as fixed factors and baseline as a covariate
SecondaryThe Change From Baseline in Visual Analogue Scales (VAS)

VAS is for assessment of RLS-associated pain. The patient was asked "How severe was your RLS associated pain in legs or arms during the past week?". No pain:0; very worst pain:10

Time frame:
Baseline and 6 weeks of treatment
Reported as:
Mean · Score on a scale
The Change From Baseline in Visual Analogue Scales (VAS)
Score on a scalePramipexolePlacebo
The Change From Baseline in Visual Analogue Scales (VAS)2.6 ± 2.53.9 ± 3
Statistical analysis
  • Pramipexole vs Placebo · ANCOVA · p = <0.0001ANCOVA with treatment and center as fixed factors and baseline as a covariate

Adverse events

Collected over 6 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pramipexole—3/202 (1.5%)81/202 (40.1%)
Placebo—0/103 (0%)25/103 (24.3%)
Most frequent serious events
Most frequent serious events
EventPramipexolePlacebo
PneumoniaInfections and infestations1/2020/103
InjuryInjury, poisoning and procedural complications1/2020/103
Transient ischaemic attackNervous system disorders1/2020/103
Most frequent other events
Most frequent other events
EventPramipexolePlacebo
DizzinessNervous system disorders35/2029/103
SomnolenceNervous system disorders28/2029/103
NauseaGastrointestinal disorders26/2028/103
HeadacheNervous system disorders20/2022/103
InsomniaPsychiatric disorders4/2026/103

Baseline characteristics

Safety Set, all randomized patients that received treatment

Age, Continuous
Age, Continuous(Years)PramipexolePlaceboTotal
Mean56.46 ± 11.8856.86 ± 11.8956.6 ± 11.87
Sex: Female, Male
Sex: Female, Male(Participants)PramipexolePlaceboTotal
Female12275197
Male8028108
08

Study locations

16 sites
  • 248.630.04 Boehringer Ingelheim Investigational Site
    Beijing, China
  • 248.630.05 Boehringer Ingelheim Investigational Site
    Beijing, China
  • 248.630.06 Boehringer Ingelheim Investigational Site
    Beijing, China
  • 248.630.07 Boehringer Ingelheim Investigational Site
    Beijing, China
  • 248.630.08 Boehringer Ingelheim Investigational Site
    Beijing, China
  • 248.630.15 Boehringer Ingelheim Investigational Site
    Guangzhou, China
  • 248.630.14 Boehringer Ingelheim Investigational Site
    Haerbin, China
  • 248.630.10 Boehringer Ingelheim Investigational Site
    Hangzhou, China
  • 248.630.09 Boehringer Ingelheim Investigational Site
    Nanjing, China
  • 248.630.12 Boehringer Ingelheim Investigational Site
    Qingdao, China
  • 248.630.01 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 248.630.02 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 248.630.03 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 248.630.16 Boehringer Ingelheim Investigational Site
    Suzhou, China
  • 248.630.13 Boehringer Ingelheim Investigational Site
    Wuhan, China
  • 248.630.11 Boehringer Ingelheim Investigational Site
    Xian, Shanxi Province, China
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2010, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2008
First posted
Apr 8, 2008
Start
Apr 2008
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
Mar 3, 2010
Last update
Jun 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00654498
Responsible party
Sponsor
First posted
Apr 8, 2008
Start date
Apr 2008
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Mar 3, 2010
Last update
Jun 9, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion